Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomics Analysis of Trop2 Xenograft Prostate Tumors

ABSTRACT: Shotgun proteomic analysis of LNCaP-Trop2-OV tumor xenografts and LNCaP-RFP control tumors

INSTRUMENT(S): LTQ Orbitrap Elite

ORGANISM(S): Homo Sapiens (human) Mus Musculus (mouse)

TISSUE(S): Prostate Gland

DISEASE(S): Prostate Cancer

SUBMITTER: Sharon Pitteri

LAB HEAD: Sharon Pitteri

PROVIDER: PXD039272 | Pride | 2023-01-05

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	Byonic_Search_Parameters.txt	Txt
	EC07_012918_01.raw	Raw
	EC07_012918_02.raw	Raw
	EC07_012918_03.raw	Raw
	EC07_012918_Human_01.xlsx	Xlsx

Items per page:

1 - 5 of 39

Publications

Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1.

Hsu En-Chi EC Rice Meghan A MA Bermudez Abel A Marques Fernando Jose Garcia FJG Aslan Merve M Liu Shiqin S Ghoochani Ali A Zhang Chiyuan Amy CA Chen Yun-Sheng YS Zlitni Aimen A Kumar Sahil S Nolley Rosalie R Habte Frezghi F Shen Michelle M Koul Kashyap K Peehl Donna M DM Zoubeidi Amina A Gambhir Sanjiv S SS Kunder Christian A CA Pitteri Sharon J SJ Brooks James D JD Stoyanova Tanya T

Proceedings of the National Academy of Sciences of the United States of America 20200113 4

Resistance to androgen deprivation therapy, or castration-resistant prostate cancer (CRPC), is often accompanied by metastasis and is currently the ultimate cause of prostate cancer-associated deaths in men. Recently, secondary hormonal therapies have led to an increase of neuroendocrine prostate cancer (NEPC), a highly aggressive variant of CRPC. Here, we identify that high levels of cell surface receptor Trop2 are predictive of recurrence of localized prostate cancer. Moreover, Trop2 is signif ...[more]

PMID: 31932422

Similar Datasets

Oncogene-Mediated Metabolic Gene Signature Predicts Breast Cancer Outcome

Project description:We performed shotgun protoemic analysis of tumor samples from HCC1806 shCtrl and shTrop2 xenograft mice.

2021-12-19 | PXD028335 | Pride

Pulmonary metastasis in xenograft model after orthotopic implantation

Project description:Metastasis is a major factor for mortality in patients with hepatocellular carcinoma (HCC). Thus, there is a need for predictive biomarker(s) for detecting the tipping point before metastasis, so as to prevent further deterioration. To discover early warning signals of pulmonary metastasis in HCC, we analysed time-series gene expression data in the spontaneous pulmonary metastasis mouse HCCLM3-RFP model with our novel dynamic network biomarker (DNB) method. To simulate tumour growth and metastasis in patient livers, we used the spontaneous pulmonary metastasis mouse model, HCCLM3-RFP, which involves the orthotopic transplanted human HCCLM3 cell line labelled with a stable fluorescent protein.We observed that, hepatic tumours in orthotopic xenograft HCCLM3-RFP mice grew gradually from the second to the fifth week after orthotopic implantation in the primary liver tissue, whereas spontaneous pulmonary metastasis occurredonly at the last time point (the fifth week after orthotopic implantation).Thus, we chose the second, third, fourth, and fifth weeks after orthotopic implantation as observation points to collect liver tumours of five orthotopic xenograft mice at each time point and to assess the whole-genome expression.

2017-06-01 | GSE94016 | GEO

Murine Vaginal Lavage Spectra for OVCAR Xenograft Study

Project description:Mass spectra were obtained from murine vaginal lavages from an ovarian cancer (OVCAR-8-RFP) xenograft study in which samples were collected over an eight week period. Spectra were collected using linear positive mode with a 4,000 - 20,000 m/z range.

2019-03-24 | MSV000083628 | MassIVE

Protein Signatures to Distinguish Aggressive from Indolent Prostate Cancer

Project description:We performed a mass spectrometry-based proteomic analysis of normal and malignant prostate tissues from 22 men who underwent surgery for prostate cancer. Prostate cancer samples included Grade Groups (3 to 5), with 8 patients experiencing recurrence and 14 without evidence of recurrence with a mean of 6.8 years of follow-up.

2022-05-04 | PXD028118 | Pride

SU086 Treatment for Advanced Prostate Cancer

Project description:We tested a novel small molecule, SU086, as a therapeutic strategy for advanced prostate cancer. Proteomic analysis was performed on treated cell lines and controls to identify protein differences. Cellular thermal shift assay (CETSA) was used to determine the interaction of SU086 with proteins.

2022-04-01 | PXD030524 | Pride

Identification of a 5-gene Signature Panel for the Prediction of Prostate Cancer Progression

Project description:Quantitative proteomics analysis was performed on two samples of localized prostate tumors from one patient (R40) and eight samples from metastatic prostate cancer sites. One sample from the right lung, one sample from the peritoneal lymph node, and two samples from the mediastinal lymph node were collected from one patient (R43). One sample from the liver and one sample from kidney were collected from another patient (R45). One sample from the periaortic lymph node and one sample from the dura were collected from another patient (R55).

2024-11-21 | PXD056300 | Pride

RNAseq of mitral valves from Fbn1 C1039G/+ mice with or without CCR2 deficiency

Project description:Mitral valves were isolated from 2-month-old mice with the following 4 genotypes: 1) CCR2 RFP/+ (Chet), 2) CCR2 RFP/RFP (Cko), 3) Fbn1 C1039G/+; CCR2 RFP/+ (FhetChet), 4) Fbn1 C1039G/+; CCR2 RFP/RFP (FhetCko). N=4 for each genotype. Total RNA was extracted from mitral valves individually for gene expression profiling.

2023-01-01 | GSE202780 | GEO

Phosphoproteomics and Morphology of Red Blood Cells treated by Protein-Tyrosine-Phosphatases Inhibitor

Project description:Phosphorylation of proteins is involved in cell functions, of which cytoskeleton organization. In particular, the phosphotyrosine (pY) has been reported to play a role in red blood cell (RBC) functions. During the storage of RBC in the context of transfusion medicine, cells suffer from storage lesions that affect energy metabolism as well as cell morphology. In the present research work, RBCs were treated (in absence of calcium) with a protein tyrosine phosphatase inhibitor (orthovanadate, OV) to trigger phosphorylation allowing to investigate this effect on RBCs during the storage. Erythrocytes were studied by phosphoproteomics, Western blot analyses and cell morphology by digital holographic microscopy in presence of kinase inhibitors. The OV treatment triggered phosphorylation events, that disappeared during the storage. As a result, 609 phosphoproteins containing 5’298 phosphosites were detected in the membrane extract, of which 43 pY were up- or down-regulated. Following these phosphorylation processes, shape of RBCs shifted from discocytes to spherocytes, and the addition of kinase inhibitors (KIs) inhibited this transition by counteracting the OV treatment. In addition, the different KIs used highlighted potentially two mechanisms involving membrane proteins and playing a role in RBC shape. The capacity of RBCs to maintain their function is central in transfusion medicine and the presented results contribute to a better understanding of RBC biology.

2024-01-26 | PXD039914 | Pride

Sorted MDMs with RFP+GFP+ or RFP+GFP- Mtb

Project description:Sorted MDMs with RFP+GFP+ or RFP+GFP- Mtb

| PRJNA542934 | ENA

LNCAP xenograft prostate cancer progression model in NOD-SCID mice

Project description:Xenografts are useful in vivo tumour models for investigating cancer progression, therapeutic responses and predicting anti-cancer drug response in patients with cancer of a similar phenotype. We have generated bulk RNA-seq data from LNCaP xenografts of a large and well-annotated prostate cancer progression study, investigating responsiveness and subsequent resistance to therapies targeting the androgen receptor (AR). LNCaP xenograft tumour establishment and initial growth are dependent on androgens in male mice (PRE-CX / pre-castration group). Upon castration, AR activity and tumour growth are suppressed (POST-CX / post-castration group), however, this initial responsiveness to castration reproducibly gives way to castration-resistance (CRPC / castration-resistant prostate cancer). Further treatment of CRPC with the AR targeting drug enzalutamide (ENZ) initially provides a therapeutic response (ENZ Sensitive; ENZS), however, resistance emerges in time (ENZ Resistant; ENZR).

2022-09-07 | GSE211856 | GEO